Zantac / Ranitidine (NDMA Cancer) Attorney in Los Angeles, California

Zantac Litigation in Los Angeles

Los Angeles is one of the nation's premier pharmaceutical litigation hubs. The LA Superior Court's Complex Civil Division has experience with large-scale drug litigation and applies the Frye/Kelly standard for novel scientific expert testimony. This standard — requiring general acceptance in the relevant scientific community — has been applied more favorably than the federal Daubert standard that caused the MDL dismissal. Multiple LA Zantac cases have survived defense expert challenges. The federal Zantac MDL (No. 2924, S.D. Florida) was largely dismissed in 2022 after Judge Robin Rosenberg excluded plaintiffs' causation experts under Daubert. However, the Delaware Superior Court under Judge Vivian Medinilla continues to actively hear Zantac cases and has allowed causation experts to proceed. Defendants Sanofi, Boehringer Ingelheim, GSK, and Pfizer are all actively litigating in Delaware. For most claimants, filing in Delaware Superior Court through national plaintiffs' counsel is now the primary path forward.

Cancer Resources for LA Zantac Claimants

Los Angeles-area Zantac claimants who were diagnosed with bladder, esophageal, stomach, or colorectal cancer after prolonged ranitidine use should obtain complete medical records from their treating oncologist before consulting an attorney. Pharmacy records documenting OTC or Rx ranitidine purchase history are critical evidence. National plaintiffs' counsel with Zantac experience can coordinate filing in California Superior Court or Delaware Superior Court depending on case facts and diagnosis timing.